News & Updates

Individuals with multiple nevi and high genetic predisposition to melanoma appear to have the highest risks of developing second primary melanomas, according to a study.

Treatment with lebrikizumab, when combined with low- to mid-potency topical corticosteroid (TCS), helps reduce disease severity in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD), with a safety profile consistent with that reported in previous AD studies, according to the phase III ADhere trial.

Adalimumab for the treatment of hidradenitis suppurativa appears to be less effective in patients with obesity, a study has found.

In patients with atopic dermatitis (AD), treatment with the IL-13 cytokine-targeting tralokinumab appears to directly or indirectly improves skin microbial dysbiosis, reports a new trial.

Long-term exposure to air pollutants, including gases and particulate matter, may increase the risk of developing atopic dermatitis (AD), according to a recent study.

In psoriasis patients, treatment with cyclosporin may increase the risk of malignancy without nonmelanoma skin cancer, a recent study has found. Biologic or phototherapy have no such impact.